Back to List View Graph View

Durvalumab

Durvalumab is a human monoclonal antibody that targets CD274 molecule, a protein that plays a crucial role in the immune system's ability to recognize and attack cancer cells.

Where the papers sit

16 papers from the last 6 months study durvalumab directly · updated from PubMed 16 Nov 2026

  • Biomarker-Guided Cancer Immunotherapy

    Lung cancer studies are shifting durvalumab from an unselected checkpoint strategy toward biomarker- and mechanism-guided use. EGFR mutations, DNA hypomethylation, Ras status and out-of-field recurrence are examined as predictors of benefit or failure across NSCLC and small-cell disease. Ceralasertib combinations and platinum-etoposide regimens test ways to overcome resistance, while population pharmacokinetics links exposure to outcomes. Nephrotic syndrome and organizing pneumonia, plus exploratory use in triple-negative breast cancer, underscore unresolved safety and generalizability.

    8 papers · 50%

  • Immunotherapy in Liver Cancer

    Unresectable hepatocellular carcinoma is being approached with dual checkpoint blockade or PD-L1/VEGF inhibition, with durvalumab–tremelimumab and atezolizumab–bevacizumab compared through response and progression-free survival. Pretreatment CD8+ T-cell abundance and DCP may help explain or predict divergent benefit. Trials are adding lenvatinib or transarterial chemoembolisation, while intratumoral IL12 mRNA plus durvalumab extends immune activation into broader solid-tumor testing. The main gap is selecting patients and combinations without sacrificing safety.

    5 papers · 31.2%

  • Perioperative Immunotherapy in Solid Tumors

    Perioperative durvalumab is moving into curative-intent treatment with cisplatin-based chemotherapy for muscle-invasive bladder cancer and FLOT for resectable gastric or gastro-oesophageal junction cancer. In NIAGARA, event-free survival and mixture-cure analyses frame benefit as durable disease control, not only delayed relapse. Neoadjuvant tremelimumab remains an adjunct under evaluation rather than a settled standard. The open question is whether perioperative checkpoint blockade improves cure fractions across tumour types.

    3 papers · 18.8%

Papers

The 16 papers from the last 6 months that study durvalumab directly, newest first, by theme and by study type. Study types come from PubMed publication types and MeSH headings.

By theme

Biomarker-Guided Cancer Immunotherapy (8)
  1. Population Pharmacokinetics and Exposure-response Analysis of Durvalumab in Patients with Limited-stage Small-cell Lung Cancer in the Phase 3 ADRIATIC Study. The AAPS journal · 28 Sept 2026 PMID 42806195
  2. Ceralasertib plus Durvalumab in Ras Mutant and Ras Wild-Type Advanced Non-Small Cell Lung Cancer: Two Cohorts of the Phase II Platform National Lung Matrix Trial. Clinical cancer research : an official journal of the American Association for Cancer Research · 9 Sept 2026 PMID 42714874
  3. Durvalumab-associated nephrotic syndrome and organizing pneumonia: a case report. CEN case reports · 2 Sept 2026 PMID 42684586
  4. Association Between EGFR Mutation Status and Out-of-field Recurrence in Locally Advanced Unresectable Non-small Cell Lung Cancer Treated With Chemoradiotherapy and Durvalumab Consolidation. Anticancer research · 31 Aug 2026 PMID 42674719
  5. DNA hypomethylation identifying clinical benefit subgroup of small-cell lung cancer: multi-omics analysis of a phase II trial with durvalumab plus olaparib as maintenance therapy. Journal for immunotherapy of cancer · 14 Aug 2026 PMID 42601174
  6. Development of an externally controlled trial from a single-arm study to assess first-line immunochemotherapy in advanced large cell neuroendocrine lung carcinomas: a study protocol from the FIRST-NEC GFPC 01-2022 trial. BMJ open · 29 Jul 2026 PMID 42526918
  7. Durvalumab plus etoposide-platinum in patients with epidermal growth factor receptor (EGFR)-mutated advanced NSCLC and neuroendocrine transformation after first-line osimertinib: ORCHARD. Lung cancer (Amsterdam, Netherlands) · 26 Jun 2026 PMID 42361644
  8. Durvalumab plus Paclitaxel, with or without Capivasertib or Oleclumab, in Patients with Locally Advanced/Metastatic Triple-Negative Breast Cancer. Clinical cancer research : an official journal of the American Association for Cancer Research · 26 May 2026 PMID 42189888
Immunotherapy in Liver Cancer (5)
  1. Patterns of Response to Durvalumab Plus Tremelimumab and Atezolizumab Plus Bevacizumab in Patients With Unresectable Hepatocellular Carcinoma. Anticancer research · 31 Aug 2026 PMID 42674706
  2. Durvalumab and tremelimumab, with or without lenvatinib, combined with transarterial chemoembolisation in participants with embolisation-eligible hepatocellular carcinoma (EMERALD-3): a global, randomised, open-label, sponsor-blinded, phase 3 study. The Lancet. Oncology · 24 Aug 2026 PMID 42636832
  3. Safety and Efficacy of Intratumoral MEDI1191, an IL12 mRNA Lipid Nanoparticle, plus Intravenous Durvalumab in Patients with Advanced Solid Tumors: A First-in-Human Study. Clinical cancer research : an official journal of the American Association for Cancer Research · 18 Aug 2026 PMID 42611979
  4. Baseline DCP May Modify Response to Atezolizumab-Bevacizumab Versus Durvalumab-Tremelimumab in Unresectable HCC. Liver international : official journal of the International Association for the Study of the Liver · 20 Jul 2026 PMID 42477505
  5. Pretreatment Tumor-infiltrating CD8+ T Cell Numbers Are Associated With the Response to Tremelimumab Plus Durvalumab in Hepatocellular Carcinoma. Anticancer research · 29 Jun 2026 PMID 42373240
Perioperative Immunotherapy in Solid Tumors (3)
  1. Perioperative durvalumab plus fluorouracil, leucovorin, oxaliplatin, and docetaxel for resectable gastric and gastro-oesophageal junction adenocarcinoma (MATTERHORN): final results of overall survival and event-free survival by pathological response in a global, randomised, double-blind, placebo-controlled, multicentre, phase 3 trial. Lancet (London, England) · 9 Sept 2026 PMID 42716074
  2. Mixture cure model analysis of event-free survival in the NIAGARA Trial: Quantifying the cure fraction benefit of perioperative durvalumab in muscle-invasive bladder cancer. Urologic oncology · 5 Jun 2026 PMID 42247881
  3. Neoadjuvant Durvalumab ± Tremelimumab in Combination With Dose-Dense Methotrexate, Vinblastine, Doxorubicin, and Cisplatin in Muscle-Invasive Bladder Carcinoma: Results of the Phase I/II NEMIO Study. Journal of clinical oncology : official journal of the American Society of Clinical Oncology · 26 May 2026 PMID 42190158

By study type

Clinical trials (11)
  1. Population Pharmacokinetics and Exposure-response Analysis of Durvalumab in Patients with Limited-stage Small-cell Lung Cancer in the Phase 3 ADRIATIC Study. The AAPS journal · 28 Sept 2026 PMID 42806195
  2. Perioperative durvalumab plus fluorouracil, leucovorin, oxaliplatin, and docetaxel for resectable gastric and gastro-oesophageal junction adenocarcinoma (MATTERHORN): final results of overall survival and event-free survival by pathological response in a global, randomised, double-blind, placebo-controlled, multicentre, phase 3 trial. Lancet (London, England) · 9 Sept 2026 PMID 42716074
  3. Ceralasertib plus Durvalumab in Ras Mutant and Ras Wild-Type Advanced Non-Small Cell Lung Cancer: Two Cohorts of the Phase II Platform National Lung Matrix Trial. Clinical cancer research : an official journal of the American Association for Cancer Research · 9 Sept 2026 PMID 42714874
  4. Durvalumab and tremelimumab, with or without lenvatinib, combined with transarterial chemoembolisation in participants with embolisation-eligible hepatocellular carcinoma (EMERALD-3): a global, randomised, open-label, sponsor-blinded, phase 3 study. The Lancet. Oncology · 24 Aug 2026 PMID 42636832
  5. Safety and Efficacy of Intratumoral MEDI1191, an IL12 mRNA Lipid Nanoparticle, plus Intravenous Durvalumab in Patients with Advanced Solid Tumors: A First-in-Human Study. Clinical cancer research : an official journal of the American Association for Cancer Research · 18 Aug 2026 PMID 42611979
  6. DNA hypomethylation identifying clinical benefit subgroup of small-cell lung cancer: multi-omics analysis of a phase II trial with durvalumab plus olaparib as maintenance therapy. Journal for immunotherapy of cancer · 14 Aug 2026 PMID 42601174
  7. Development of an externally controlled trial from a single-arm study to assess first-line immunochemotherapy in advanced large cell neuroendocrine lung carcinomas: a study protocol from the FIRST-NEC GFPC 01-2022 trial. BMJ open · 29 Jul 2026 PMID 42526918
  8. Durvalumab plus etoposide-platinum in patients with epidermal growth factor receptor (EGFR)-mutated advanced NSCLC and neuroendocrine transformation after first-line osimertinib: ORCHARD. Lung cancer (Amsterdam, Netherlands) · 26 Jun 2026 PMID 42361644
  9. Mixture cure model analysis of event-free survival in the NIAGARA Trial: Quantifying the cure fraction benefit of perioperative durvalumab in muscle-invasive bladder cancer. Urologic oncology · 5 Jun 2026 PMID 42247881
  10. Neoadjuvant Durvalumab ± Tremelimumab in Combination With Dose-Dense Methotrexate, Vinblastine, Doxorubicin, and Cisplatin in Muscle-Invasive Bladder Carcinoma: Results of the Phase I/II NEMIO Study. Journal of clinical oncology : official journal of the American Society of Clinical Oncology · 26 May 2026 PMID 42190158
  11. Durvalumab plus Paclitaxel, with or without Capivasertib or Oleclumab, in Patients with Locally Advanced/Metastatic Triple-Negative Breast Cancer. Clinical cancer research : an official journal of the American Association for Cancer Research · 26 May 2026 PMID 42189888
Observational studies and case reports (5)
  1. Durvalumab-associated nephrotic syndrome and organizing pneumonia: a case report. CEN case reports · 2 Sept 2026 PMID 42684586
  2. Association Between EGFR Mutation Status and Out-of-field Recurrence in Locally Advanced Unresectable Non-small Cell Lung Cancer Treated With Chemoradiotherapy and Durvalumab Consolidation. Anticancer research · 31 Aug 2026 PMID 42674719
  3. Patterns of Response to Durvalumab Plus Tremelimumab and Atezolizumab Plus Bevacizumab in Patients With Unresectable Hepatocellular Carcinoma. Anticancer research · 31 Aug 2026 PMID 42674706
  4. Baseline DCP May Modify Response to Atezolizumab-Bevacizumab Versus Durvalumab-Tremelimumab in Unresectable HCC. Liver international : official journal of the International Association for the Study of the Liver · 20 Jul 2026 PMID 42477505
  5. Pretreatment Tumor-infiltrating CD8+ T Cell Numbers Are Associated With the Response to Tremelimumab Plus Durvalumab in Hepatocellular Carcinoma. Anticancer research · 29 Jun 2026 PMID 42373240